June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Long-Term Outcome of Second Ahmed Valves in Glaucoma
Author Affiliations & Notes
  • Nucharee Parivisutt
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • Reza Alizadeh
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • grace ang
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • Esteban Morales
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • Nima Fatehi
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • Joseph Caprioli
    Glaucoma, Jules Stein Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Nucharee Parivisutt, None; Reza Alizadeh, None; grace ang, None; Esteban Morales, None; Nima Fatehi, None; Joseph Caprioli, None
  • Footnotes
    Support  RPB
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4972. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nucharee Parivisutt, Reza Alizadeh, grace ang, Esteban Morales, Nima Fatehi, Joseph Caprioli; Long-Term Outcome of Second Ahmed Valves in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4972.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the long-term outcomes of second Ahmed valve implants in eyes with glaucoma.

Methods : A retrospective review of the success rates of patients who have had a second Ahmed valve implanted in one eye from 1994 to 2016 was conducted. Success was defined with three criteria: (A) IOP ≤21 mmHg and IOP reduction of 30%; (B) IOP≤18 mmHg and IOP reduction of 20%; and (C) IOP ≤15mm Hg and IOP reduction of 25%. The primary outcome was a 5-Year Kaplan-Meier survival rate for each criterion. Other failure criteria were loss of light perception, requirement for additional glaucoma surgery, hypotony, and serious complications.

Results : 148 eyes from 140 patients (58 males and 82 females) were included with a median follow-up of 3.5 years (interquartile range [IQR] 0.9 to 6.6 years). The median age was 74.0 years (IQR: 41.5 to 86.6 years). The interval between first and second surgeries was 2 weeks to 11.3 years (median 1.9 years, with IQR: 0.6 to 3.9 years. Diagnoses were POAG (26%), congenital glaucoma (16%), secondary ACG (12%), uveitic glaucoma (11%) and NVG (10%). The 5-year Kaplan-Meier survival rates were 35.4% (±4.1%), 18.5% (±3.8%) and 10.2 % (±3.6%) for criteria A, B and C, respectively (Figure 1).

Conclusions : A second AGV is effective in reducing IOP in patients who require additional IOP lowering after a first AGV. The success rates are comparable to primary AGV implantation in POAG patients and are higher than in patients with secondary glaucoma, such as uveitic glaucoma or silicone oil induced glaucoma. The success rate is higher than in patients who had prior failed trabeculectomy. A second AGV is a viable option in eyes with inadequate IOP control after GDD along with.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×